Sanofi SASY.PA has started discussions with investment bank Rothschild & Co about its proposed spin-off and separate listing of its Consumer Health business, which could be valued at more than $20 billion, it reported on Wednesday. Bloomberg, citing sources familiar with the matter.
This activity, which notably manufactures Doliprane, has attracted initial interest from large private equity companies who are evaluating a potential acquisition, adds Bloomberg.
(Written by Victor Goury-Laffont and Bertrand Boucey)